(Q34585205)

3 August 2017

1 reference

title

Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors (English)

1 reference

3 August 2017

1 reference

Paul E Goss

1

1 reference

PubMed ID

11929341

3 August 2017

Kathrin Strasser

series ordinal

2

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

62

1 reference

3 August 2017

957-966

1 reference

3 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200262060-00007

3 August 2017

0 references

cites work

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription

1 reference

12 December 2020

Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging

1 reference

12 December 2020

The potential of aromatase inhibitors in breast cancer prevention

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor

1 reference

12 December 2020

Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies

1 reference

12 December 2020

Medical and surgical adrenalectomy in patients with advanced breast carcinoma

1 reference

12 December 2020

Estrogen receptor variants in clinical breast cancer

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer

1 reference

12 December 2020

Aromatase inhibitors--mechanisms for non-steroidal inhibitors

1 reference

12 December 2020

A reassessment of the role of breast tumor aromatization

1 reference

12 December 2020

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

Aromatase inhibitors: rationale for use following antiestrogen therapy.

1 reference

12 December 2020

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA

1 reference

12 December 2020

Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration

1 reference

12 December 2020

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

12 December 2020

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

12 December 2020

Aromatase activity and expression in breast cancer and benign breast tissue stromal cells

1 reference

12 December 2020

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

12 December 2020

Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities

1 reference

12 December 2020

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Clinical significance of tamoxifen withdrawal response

1 reference

12 December 2020

Current perspectives on aromatase inhibitors in breast cancer

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Aromatase inhibitors and their antitumor effects in model systems

1 reference

12 December 2020

Aromatase expression in health and disease

1 reference

12 December 2020

Regulation of aromatase activity within the breast

1 reference

12 December 2020

Aromatase inhibitors--mechanisms of steroidal inhibitors

1 reference

12 December 2020

Identification of a promoter and a silencer at the 3'-end of the first intron of the human aromatase gene.

1 reference

12 December 2020

Oestradiol synthesis from C19 steroids by human breast cancers

1 reference

12 December 2020

Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary gl

1 reference

12 December 2020

Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.

1 reference

12 December 2020

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

12 December 2020

Oestrogen receptor mutants and variants in breast cancer

1 reference

12 December 2020

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

1 reference

12 December 2020

Biological significance of aromatase activity in human breast tumors

1 reference

12 December 2020

Status of aromatase inhibitors in relation to other breast cancer treatment modalities

1 reference

12 December 2020

The importance of local synthesis of estrogen within the breast

1 reference

12 December 2020

Concentration of sex steroids in adipose tissue after menopause

1 reference

12 December 2020

Peptide antagonists of the human estrogen receptor

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

Aberrant expression of aromatase in breast cancer tissues

1 reference

12 December 2020

Relationship between tumour aromatase activity, tumour characteristics and response to therapy

1 reference

12 December 2020

10.2165/00003495-200262060-00007

Identifiers

DOI

1 reference

PubMed ID

11929341

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

11929341